M&A Deal Summary

DiaSorin Acquires Luminex

On April 12, 2021, DiaSorin acquired medical products company Luminex for 1.8B USD

Acquisition Highlights
  • This is DiaSorin’s 1st transaction in the Medical Products sector.
  • This is DiaSorin’s largest (disclosed) transaction.
  • This is DiaSorin’s 2nd transaction in the United States.
  • This is DiaSorin’s 1st transaction in Texas.

M&A Deal Summary
Date 2021-04-12
Target Luminex
Sector Medical Products
Buyer(s) DiaSorin
Deal Type Add-on Acquisition
Deal Value 1.8B USD
Advisor(s) Perella Weinberg Partners (Financial)
DLA Piper (Legal)

Target

Luminex

Austin, Texas, United States
Luminex is a developer, manufacturer and marketer of proprietary instruments and assays utilizing xMAP open-architecture, multi-analyte platform and MultiCode real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex was founded in 1995 and is based in Austin, Texas.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

DiaSorin

Saluggia, Italy
Category Company
Founded 1968
Sector Healthcare Services
Employees3,184
Revenue 1.4B EUR (2022)
DESCRIPTION

DiaSorin has been developing, producing and marketing reagent kits for in vitro diagnostics worldwide. DiaSorin was founded in 1968 and is based in Saluggia, Italy.

DEAL STATS #
Overall 2 of 2
Sector (Medical Products) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Texas) 1 of 1
Country (United States) 2 of 2
Year (2021) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-30 Focus Diagnostics

Cypress, California, United States

Focus Diagnostics, Inc. is a developer of immunodiagnostic and molecular diagnostic products.

Buy $300M
Mergr

Product

Company

Legal